GET DAILY SIGNALSWhy Is Starling Oncology (STLN) Stock Down -37.76% Today?
Key Takeaways
- Shares of STLN tumbled about 37.76% to roughly $4.17, down from the prior session's close of $6.70.
- The primary catalyst was a sharply reduced forward outlook: management cut its 2026 capitated revenue expectation to about $110 million from roughly $150 million.
- Secondary drivers included a wider-than-expected third-quarter GAAP loss and a delayed Florida expansion that undercut the company's growth narrative.
- The selloff follows a strong run-up, with shares having climbed sharply year-to-date, leaving the stock vulnerable to any guidance reset.
- Traders are now watching the 2027 capitation ramp, fourth-quarter free cash flow, and the status of delegated contracts in Nevada and Oregon.
- For deeper analysis, explore detailed Price Targets, Earnings history, and AI-driven Forecast pages.
- Discover the strongest-performing automated strategies under current market conditions on Tickeron's Trending AI Robots page.
Opening Summary
Starling Oncology, Inc. (Nasdaq: STLN) — formerly The Oncology Institute — is one of the largest value-based community oncology groups in the United States, providing specialized cancer care, infusion, clinical trials, and specialty pharmacy services. Shares plunged about 37.76% on Thursday, trading near $4.17 compared with a prior close of $6.70, as investors reacted to third-quarter results and, more importantly, a sharp downward revision to the company's capitated revenue outlook.
Capitation Guidance Cut Shakes the Growth Story
The most damaging headline was not the earnings miss itself but the reset in expectations. Starling Oncology cut its 2026 capitated revenue forecast to approximately $110 million, down from roughly $150 million — a target management had reaffirmed through three prior calls. Capitation, the company's core value-based revenue model, is central to its long-term growth thesis, so reducing that base by more than a quarter directly undercut the bull case that had supported the stock's 2026 rally.
The revision was tied to an operational delay in Florida, where a statewide expansion with three anchor plan partners had already slipped from the third quarter to the fourth and now will not proceed immediately. Management cited an operational and timing issue. The delayed launch also muddied the picture for 2027, where the previously framed "100% capitated growth" target now implies a much smaller base. Additionally, a Nevada delegated contract announced in the second quarter was not mentioned among fourth-quarter launches.
Mixed Third-Quarter Results
The September-quarter results pointed in conflicting directions. The company posted a GAAP loss of $0.13 per share on revenue of $169.77 million, missing the consensus loss estimate of roughly $0.07 by a wide margin while edging past the $168.2 million revenue consensus. Adjusted EBITDA was positive at $3.4 million — a second consecutive positive quarter and well above management's $0.5 million to $1.5 million outlook.
Still, growth is clearly decelerating. Consolidated revenue rose 24.3% year over year, down from 35% in the second quarter, while fee-for-service revenue fell 21% despite rising visit volumes. Specialty pharmacy remained a bright spot, with revenue up 44%, though management cautioned that part of the margin strength reflected non-recurring rebates and price movements.
Analyst Reaction and Sentiment
The guidance cut prompted immediate repricing. Analysts trimmed expectations, with at least one firm lowering its price target on STLN to $8 from $10 while maintaining a Buy rating, describing the updated capitated revenue guide as "annoying" even as the rest of the business was characterized as "soaring." The mixed messaging — solid operational progress alongside a reduced top-line trajectory — left investors with little reason to defend an already extended valuation.
Market Context and Trading Activity
The decline occurred on elevated volume relative to recent sessions, reflecting broad-based repositioning rather than isolated selling. The move diverged sharply from the broader market, as major indices were not under comparable pressure, underscoring that the selloff was company-specific. After a sharp year-to-date advance, the stock had little technical support nearby, and the break below prior levels accelerated momentum selling once the guidance reset removed the fundamental anchor.
What Comes Next for STLN
Investors will focus on whether the company can restore credibility around its capitation pipeline. Management cited a known 2027 capitation pipeline above $1 billion in annualized spend, and Oregon went live in October as its first delegated capitation contract outside Florida. Key watch items include the timing of the Florida relaunch, fourth-quarter free cash flow — where guidance implies meaningful near-term cash burn — and whether specialty pharmacy momentum can offset softer fee-for-service trends. Risks remain around execution, liquidity, and the pace of new member onboarding.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, giving investors a range of automated approaches to evaluate. Explore the page to see which AI-driven strategies are currently outperforming the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
STLN in +11.04% Uptrend, growing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where STLN advanced for three days, in 258 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 58 cases where STLN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
STLN moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STLN as a result. In 57 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for STLN turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 32 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STLN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-27.408) is normal, around the industry mean (203.977). P/E Ratio (-23.103) is within average values for comparable stocks, (20.904). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.097) among similar stocks. P/S Ratio (1.124) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. STLN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STLN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement